According to data from the Ho Chi Minh City Stock Exchange (HOSE), three institutional investors linked to internal figures at Imexpharm Pharmaceutical JSC (Ticker: IMP) have registered to sell significant portions of their holdings, effectively reducing their ownership or exiting the company entirely.
Breakdown of the proposed transactions:
-
SK Investment Vina III Pte. Ltd: The fund has registered to sell over 68.8 million shares. Upon completion, its stake is expected to drop to approximately 3%, leaving it with about 4.6 million shares.
-
Binh Minh Kim Investment JSC: This entity plans to divest its entire holding of more than 15 million shares, bringing its ownership to 0%.
-
KBA Investment JSC: Similarly, KBA has registered to liquidate its total holding of over 11.3 million shares.
These transactions are scheduled to take place between April 17 and April 21, 2026. All three organizations are associated with Mr. Woo Sungmin, a member of Imexpharm’s Board of Directors. This coordinated divestment follows news from early March regarding Lian SGP Holding (a subsidiary of China’s Livzon Pharmaceutical Group) launching a tender offer to acquire a controlling 77.94% stake in the pharmaceutical firm.
Source: https://suckhoedoisong.vn/nhom-co-dong-lon-dong-loat-thoai-von-tai-imexpharm-169260415180355115.htm